<DOC>
	<DOC>NCT00336986</DOC>
	<brief_summary>This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.</brief_summary>
	<brief_title>Efficacy Study of IL-21 to Treat Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed surgically incurable metastatic melanoma Patients must have measurable disease ECOG performance status of 0 or 1 Expected life expectancy at least 4 months History of and signs/symptoms of uncontrolled brain metastases or edema. Previous treatment with chemotherapy or any biological anticancer drug (prior adjuvant therapy with interferonalpha is permitted as long as treatment was completed at least six months prior to study entry.) Radiotherapy: Radiation therapy within 4 weeks prior to entering the study. Receipt of any investigational drug for treatment of metastatic melanoma prior to this trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>